Sugi Predict

Sugi Predict / Compounds / SCHEMBL5833366

SCHEMBL5833366

SCHEMBL5833366

O=C([C@@H](O)CO)N1CC=C(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CC1

nearest known ligand 0.57

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 11/20 0.57
▸ CYP2E1 P05181 1/20 0.46
▸ CALML3 P27482 4/20 0.41
▸ F10 P00742 2/20 0.39
▸ LMNA P02545 1/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ SDHA P31040 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5834248 0.91 MAOA (0.49) MAOACYP2E1CALML3F10LMNA
SCHEMBL5833884 0.90 MAOA (0.60) MAOACYP2E1CALML3F10LMNA
SCHEMBL5834526 0.89 MAOA (0.45) MAOACYP2E1F10
SCHEMBL5833333 0.87 MAOA (0.45) MAOACALML3F10MAOB
SCHEMBL5834174 0.86 MAOA (0.58) MAOACYP2E1CALML3LMNAPTGS1
SCHEMBL6762704 0.86 MAOA (0.57) MAOACYP2E1CALML3F10LMNA
SCHEMBL7081938 0.86 CALML3 (0.41) MAOACALML3
SCHEMBL7077029 0.86 CALML3 (0.41) MAOACALML3
SCHEMBL6762707 0.86 MAOA (0.57) MAOACYP2E1CALML3F10MAOB
SCHEMBL6762702 0.86 MAOA (0.57) MAOACYP2E1CALML3F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734200-B1 ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS ASTRAZENECA AB (SE) 2004-05-11 — — US claimed
US-20030207899-A1 Heterocyclylaminomethyloxazo-lidinones as antibacterials ASTRAZENECA AB (SE) 2003-11-06 — — US claimed
EP-1121358-A1 HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS AstraZeneca AB (SE) 2001-08-08 — — EP claimed
WO-2000021960-A1 HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS ASTRAZENECA AB (SE) 2000-04-20 — — WO claimed
US-7087629-B2 Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams ASTRAZENECA AB (SE) 2006-08-08 — — US disclosed
US-6734200-B1 ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS ASTRAZENECA AB (SE) 2004-05-11 — — US disclosed
US-20030207899-A1 Heterocyclylaminomethyloxazo-lidinones as antibacterials ASTRAZENECA AB (SE) 2003-11-06 — — US disclosed
EP-1121358-A1 HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS AstraZeneca AB (SE) 2001-08-08 — — EP disclosed
WO-2000021960-A1 HETEROCYCLYL AMINO METHYLOXA ZOLIDINONES AS ANTIBACTERIALS ASTRAZENECA AB (SE) 2000-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207899-A1 Heterocyclylaminomethyloxazo-lidinones as antibacterials HDHD5, CYP8B1, LSS MAOA 652/4885CYP2E1 159/4885CALML3 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.